Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL29935681

FC(F)(F)c1cnc(OC2CCNC2)c(Cl)c1.O=C(O)C(F)(F)F

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.43
MRGPRX4 Q96LA9 1/20 0.42
GAA P10253 2/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
LMNA P02545 1/20 0.41
GLA P06280 1/20 0.41
HPGD P15428 1/20 0.41
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 1/20 0.39
RAB9A P51151 2/20 0.39
LIPE Q05469 1/20 0.39
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL23702908 1.00 SMN1; SMN2 (0.43) SMN1; SMN2MRGPRX4GAAMAPTCYP2C9
SCHEMBL23703471 0.92 CHEK1 (0.43) CYP2C19HPGDKMT2ARAB9A
SCHEMBL29994646 0.92 CHEK1 (0.43) CYP2C19HPGDKMT2ARAB9A
SCHEMBL23703470 0.92 CHEK1 (0.43) CYP2C19HPGDKMT2ARAB9A
Hydrochloric Acid SCHEMBL23703442 0.91 CHEK1 (0.42) CYP2C19HPGDKMT2ARAB9A
Hydrochloric Acid SCHEMBL23703438 0.91 CHEK1 (0.42) CYP2C19HPGDKMT2ARAB9A
Trifluoroacetic Acid SCHEMBL26620566 0.78 LIPG (0.49) LIPE
SCHEMBL18422974 0.76 CYP2C9 (0.51) SMN1; SMN2MRGPRX4GAAMAPTCYP2C9
SCHEMBL21825495 0.74 CYP2C9 (0.44) SMN1; SMN2MRGPRX4GAAMAPTCYP2C9
SCHEMBL17062172 0.74 CYP2C9 (0.44) SMN1; SMN2MRGPRX4GAAMAPTCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435061-B2 Compounds and compositions for use in treating skin disorders KAMARI PHARMA LTD. (IL) 2025-10-07 US disclosed
EP-4574822-A2 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS Kamari Pharma Ltd. (IL) 2025-06-25 EP disclosed
CN-118702672-A Compounds and compositions for treating skin disorders 卡玛瑞制药有限公司 2024-09-27 CN disclosed
CN-115335050-B Compounds and compositions for treating skin disorders 卡玛瑞制药有限公司 2024-05-17 CN disclosed
US-20240124413-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS KAMARI PHARMA LTD. (IL) 2024-04-18 US disclosed
US-11807621-B2 Compounds and compositions for use in treating skin disorders KAMARI PHARMA LTD. (IL) 2023-11-07 US disclosed
EP-4096661-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS Kamari Pharma Ltd. (IL) 2022-12-07 EP disclosed
CN-115335050-A Compounds and compositions for treating skin conditions 卡玛瑞制药有限公司 2022-11-11 CN disclosed
US-20220332697-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS KAMARI PHARMA LTD. (IL) 2022-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435061-B2 Compounds and compositions for use in treating skin disorders RDX, HAX1, F12 SMN1; SMN2 3452/4885MRGPRX4 50/4885GAA 1233/4885
US-20240124413-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS RDX, HAX1, F12 SMN1; SMN2 3452/4885MRGPRX4 50/4885GAA 1233/4885
US-11807621-B2 Compounds and compositions for use in treating skin disorders RDX, HAX1, F12 SMN1; SMN2 3452/4885MRGPRX4 50/4885GAA 1233/4885
US-20220332697-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS RDX, HAX1, F12 SMN1; SMN2 3452/4885MRGPRX4 50/4885GAA 1233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.